MedTrace Logo

Avastin for Post-photocoagulation Macular Edema

NCT00801866 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2024-05-30

No results posted yet for this study

Summary

to evaluate the efficacy of a single intravitreal bevacizumab (IVB) injection, 0.1mL (2.5mg), against panretinal photocoagulation (PRP)-induced macular thickening and visual disturbance in patients with severe nonproliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR) and good vision

Conditions

  • Macular Edema

Interventions

DRUG

Bevacizumab

Intravitreal administration

PROCEDURE

Panretinal Photocoagulation

Panretinal Photocoagulation

Sponsors & Collaborators

  • Asociación para Evitar la Ceguera en México

    lead OTHER

Principal Investigators

  • Eduarto Torres-Porras, MD · Asociación para Evitar la Ceguera en México

  • Octavio Burgos, MD · Asociación para Evitar la Ceguera en México

Study Design

Purpose
TREATMENT

Eligibility

Min Age
15 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00801866 on ClinicalTrials.gov